Neo Ivy Capital Management’s Royalty Pharma RPRX Stock Holding History

Neo Ivy Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-22,590	Closed	-$797K	–	506
2025 Q3	$797K	Buy	+22,590	New	+$818K	0.19%	173
2023 Q3	–	Sell	-38,961	Closed	-$1.2M	–	438
2023 Q2	$1.2M	Buy	+38,961	New	+$1.32M	0.63%	36
2022 Q4	$277K	Buy	7,014 +660	+10%	+$27.5K	0.19%	200
2022 Q3	$255K	Buy	+6,354	New	+$271K	0.67%	34
2022 Q2	–	Sell	-6,692	Closed	-$260K	–	581
2022 Q1	$260K	Buy	+6,692	New	+$263K	0.23%	156
2021 Q4	–	Sell	-1,102	Closed	-$54K	–	606
2021 Q3	$54K	Buy	+1,102	New	+$42.8K	0.06%	312
2021 Q1	–	Sell	-5,736	Closed	-$287K	–	604
2020 Q4	$287K	Buy	5,736 +3,912	+214%	+$166K	0.32%	107
2020 Q3	$76K	Buy	1,824 +722	+66%	+$31K	0.08%	317
2020 Q2	$54K	Buy	+1,102	New	+$54.5K	0.06%	312

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neo Ivy Capital Management's RPRX Position: Q4 2025 in Review

Neo Ivy Capital Management sold out of Royalty Pharma (RPRX) in Q4 2025, closing a stake of 22,590 shares — an estimated $797K sold.

Neo Ivy Capital Management first reported a position in RPRX in Q2 2020 and held it in 9 quarters. The position peaked at $1.2M in Q2 2023. 539 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

Neo Ivy Capital Management reported no remaining Royalty Pharma position as of Q4 2025 after selling out during the quarter.
Neo Ivy Capital Management sold 22,590 Royalty Pharma shares in Q4 2025, an estimated $797K.
Neo Ivy Capital Management first reported a position in Royalty Pharma in Q2 2020 and held it in 9 quarters.
Neo Ivy Capital Management's Royalty Pharma position peaked at $1.2M in Q2 2023.
539 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on Neo Ivy Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.